Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1998, p. 3117-3122, Vol. 42, No. 12
Antibiotic Group, Department of Medical
Microbiology, St. Bartholomew's and the Royal London School of
Medicine and Dentistry, London, E1 2AD, United
Kingdom,1 and
Section of Infectious
Diseases, Department of Internal Medicine, Hacettepe University School
of Medicine, 06100 Ankara, Turkey2
Received 13 March 1998/Returned for modification 14 July
1998/Accepted 21 September 1998
Two extended-spectrum mutants of the class D Resistance to oxyimino
cephalosporins in enterobacteria is often associated with
extended-spectrum In the present study, we describe the discovery and characterization of
a further ESBL mutant of OXA-10, also from P. aeruginosa isolates collected from Hacettepe University Hospital.
Bacterial strains and plasmids.
P. aeruginosa 906 and
961 were isolated in June 1993 from patients treated for burns at
Hacettepe University Hospital and were retained because of their
considerable resistance to ceftazidime (MIC, 128 µg/ml). P. aeruginosa PU21 ilv leu Strr
Rifr was used as a recipient in transconjugation
(14). P. aeruginosa ABD and 455, with plasmids
pMLH52 and pMLH53, encoding OXA-11 and -14 Antibiotics.
Antimicrobials tested were aztreonam and
cefepime (Bristol-Myers Squibb, Syracuse, N.Y.); cefsulodin (Novartis,
Basel, Switzerland); ceftazidime (Glaxo-Wellcome, Stevenage,
Hertfordshire, United Kingdom); piperacillin sodium, tazobactam, and
tetracycline (Wyeth-Lederle, Taplow, Berkshire, United Kingdom);
cephalothin, moxalactam, and tobramycin (Lilly, Basingstoke, Hampshire,
United Kingdom); imipenem (Merck Sharp and Dohme, Hoddesdon,
Hertfordshire, United Kingdom); ceftriaxone (Roche, Welwyn Garden City,
Hertfordshire, United Kingdom); cefotaxime and cefpirome (Roussel,
Uxbridge, Middlesex, United Kingdom); benzylpenicillin, cephaloridine,
cloxacillin, gentamicin, kanamycin, oxacillin, and rifampin (Sigma, St.
Louis, Mo.); ampicillin sodium, carbenicillin disodium, and clavulanate lithium (SmithKline Beecham, Brentford, Middlesex, United Kingdom); and
meropenem (Zeneca, Macclesfield, Cheshire, United Kingdom).
Susceptibility tests.
MICs were determined on DST agar
(Oxoid, Basingstoke, Hampshire, United Kingdom) with inocula of
104 CFU per spot, as described previously (11).
Plasmid transfer to P. aeruginosa PU21.
Logarithmic-phase cells of P. aeruginosa isolates 906 and
961 were mated with similar cultures of P. aeruginosa PU21
on DST agar (11). After overnight incubation,
transconjugants were selected on the DST agar containing ceftazidime at
25 or 50 µg/ml plus rifampin at 100 µg/ml. Where appropriate, the
mobilizing plasmid pUZ8 was first transferred from P. aeruginosa PU21(pUZ8) to the isolates, using the same plate-mating
method but with selection on DST agar containing ceftazidime at 25 µg/ml and kanamycin at 1,000 µg/ml. To confirm their presence and
to estimate their sizes, the plasmids were extracted by the method of
Kado and Liu (15) and electrophoresed at 100 V for 4 h
in 0.7% agarose gels at 4°C.
Detection of
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
OXA-16, a Further Extended-Spectrum Variant of
OXA-10
-Lactamase, from Two Pseudomonas
aeruginosa Isolates
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase OXA-10
(PSE-2) from Pseudomonas aeruginosa isolates obtained in
Ankara, Turkey, were described previously and were designated OXA-11
and -14. P. aeruginosa 906 and 961, isolated at the same
hospital, were highly resistant to ceftazidime (MIC
128 µg/ml) and produced a
-lactamase with a pI of 6.2. The MICs of
ceftriaxone, cefoperazone, cefsulodin, and cefepime were 4- to 16-fold
above the typical values for P. aeruginosa, whereas the
MICs of penicillins and cefotaxime were raised only marginally.
Ceftazidime MICs were not significantly reduced by clavulanate or
tazobactam at 4 µg/ml. Ceftazidime resistance did not transfer
conjugatively but was mobilized to P. aeruginosa PU21 by
plasmid pUZ8. Both isolates gave similar DNA restriction patterns,
suggesting that they were replicates; moreover, they yielded
identically sized BamHI fragments that hybridized with a
blaOXA-10 probe. DNA sequencing revealed that
both isolates had the same new
-lactamase, designated OXA-16, which
differed from OXA-10 in having threonine instead of alanine at position
124 and aspartate instead of glycine at position 157. The latter change
is also present in OXA-11 and -14 and seems critical to ceftazidime
resistance. Kinetic parameters showed that OXA-16 enzyme was very
active against penicillins, cephaloridine, cefotaxime, and ceftriaxone,
but hydrolysis of ceftazidime was not detected despite the ability of
the enzyme to confer resistance.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamases (ESBLs), most of which are mutants
of molecular class A
-lactamases, specifically TEM-1 and SHV-1
(2, 19). In Pseudomonas aeruginosa, on the other
hand, the most frequent mechanisms of resistance to the oxyimino
cephalosporins are derepression of the AmpC chromosomal enzyme and
up-regulation of multi-drug efflux (3, 4), and only one
extended-spectrum TEM mutant (TEM-42) has been reported (24). Nevertheless, P. aeruginosa has been a
major source of unusual ESBLs. Examples include IMP-I, the first
plasmidic zinc
-lactamase (32); PER-1, a class A enzyme
now widespread in Turkey, though not elsewhere (6, 26, 27,
30); OXA-15, an ESBL mutant of OXA-2 (7); and OXA-11
and -14, which are ESBL mutants of OXA-10 enzyme (5, 11).
OXA-11
-lactamase has two mutations compared with OXA-10, whereas
OXA-14 has only one of them. OXA-11 and -14 were produced by isolates
from Hacettepe University Hospital in Ankara, Turkey. Total-DNA
restriction profiles of these two isolates were identical, and both
carried plasmids that gave identical restriction fragments on digestion
with EcoRI (5). It is likely that the producer
isolates differed only in the presence or absence of the second
mutation in the
-lactamase gene (5).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamases, respectively
(5, 11), and their P. aeruginosa PU21
transconjugants were used as controls, together with P. aeruginosa PU21(pMLH51) as a reference producer of OXA-10
-lactamase (11, 20). Gene sequencing has confirmed that
the OXA-10 enzyme encoded by pMLH51 is identical to that encoded by plasmid R151, the prototype host of the OXA-10 gene (13).
Plasmid pUZ8 (IncP-1), determining resistance to kanamycin,
tetracycline, and mercuric chloride, was used to mobilize resistance
(12). Escherichia coli NCTC 50192 (31), with plasmids of 154, 66, 38, and 7 kb, and P. aeruginosa PU21 with plasmid pMG2 (450 kb) served as controls in
plasmid-sizing studies (29).
-lactamases and their genes.
-Lactamases
were characterized by isoelectric focusing of ultrasonic extracts
prepared from overnight nutrient agar cultures (Oxoid) (22).
For gene probing, plasmids or total DNA were extracted and digested
with BamHI and then electrophoresed on agarose, Southern blotted to nylon membrane, and hybridized with probes, exactly as
described previously for strain ABD (11). The probe for
blaOXA-10 was made by PCR amplification of a DNA
fragment corresponding to the coding region from pMLH51, using primers
ABD1 and ABD4 (Fig. 1), and was labeled
with digoxigenin (DIG DNA labelling and detection kit; Boehringer,
Lewes, East Sussex, United Kingdom).

View larger version (32K):
[in a new window]
FIG. 1.
Gene and protein sequences of OXA-16
-lactamase in
comparison to those of OXA-10, -11, and -14 enzymes. The nucleotide
sequence of blaOXA-10 described by Huovinen et
al. (13) runs from bases 57 to 957 and contains the OXA-10
coding region. Nucleotides, shown above the OXA-16 sequences, and the
deduced amino acid changes, shown below the OXA-16 sequences, indicate
differences in OXA-10, -11, and -14
-lactamase. The signal peptide
extends from amino acid residues 1 to 20, and the proposed cleavage
site is indicated by a vertical line. The underlined nucleotide
sequences represent the primers used for sequencing and PCR
amplification. Sequences corresponding to the amplification primers
ABD-1 and -4, shown in italics, have not been independently determined
for OXA-16. Boldface letters represent amino acids around the active
site. The nucleotide sequence shown corresponds to that of the OXA-16
gene, determined in this study.
Sequencing of the
-lactamase gene.
OXA-10-related genes
from clinical isolates were amplified by PCR with primers ABD1 and 5'
biotin-labelled ABD4 (Fig. 1), using the methods described previously
(5). The two DNA strands of the product were separated by
using paramagnetic beads conjugated with streptavidin (Dynabeads M-280
Streptavidin; Dynal, New Ferry, Wirral, United Kingdom) and were used
as templates for sequencing by chain termination (5), with
ABD1, ABD2, and ABD3 as primers (Fig. 1).
-Lactamase purification.
Cultures were grown overnight
with shaking in 0.6 liters of antibiotic no. 3 broth (Oxoid) at 37°C
and then diluted into 12 liters of identical fresh medium and incubated
for 5 h to yield late-logarithmic-phase cells. The bacteria were
harvested at 5,000 × g for 15 min at 37°C, washed
once in 20 mM triethanolamine buffer (pH 7.6) (buffer A), and then
resuspended in the same buffer and frozen and thawed twice. Debris was
removed by ultracentrifugation at 100,000 × g for 45 min at 4°C, and the supernatants were loaded onto columns (2.6-cm
diameter by 40 cm) of DEAE Sephadex A-50 equilibrated with buffer A. Elution was done with a gradient of 0 to 0.5 M
K2SO4 in buffer A. Fractions with
-lactamase
activity were dialyzed against 50 mM malonic acid (pH 7.0) overnight
and then adjusted to pH 4.9 (OXA-10 enzyme) or 5.0 (enzyme from isolate 906) with 0.5 M H2SO4. These solutions were
loaded on to S-Sepharose high-performance columns (1.6-cm diameter by
10 cm) (Pharmacia LKB, Milton Keynes, Buckinghamshire, United Kingdom),
which were equilibrated with 50 mM malonic acid, pH 4.9 (OXA-10) or 5.0 (enzyme from isolate 906), and eluted with a gradient of 0 to 0.5 M
K2SO4 in the same buffer. The fractions with
-lactamase activity were dialyzed against 4 liters of 50 mM
bis-Tris-H2SO4, pH 7.0. Their purity was
estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
by the system of Lugtenberg et al. (21), and the protein
concentration was determined by the microbicinchoninic acid method
(Pierce, Rockford, Ill).
Spectrophotometric
-lactamase assays.
-Lactamase
activity was assayed by UV spectrophotometry at 37°C in 0.1 M
phosphate buffer at pH 7.0. The following wavelengths were used:
ampicillin and penicillin G, 235 nm; cephaloridine, 295 nm;
cephalothin, 262 nm; cefotaxime and ceftazidime, 257 nm; cloxacillin
and oxacillin, 263 nm; and imipenem and meropenem, 297 nm. Biphasic
kinetics were analyzed by the program of De Meester et al.
(10), kindly provided by J.-M. Frère. Kinetic
parameters were determined by using the Enzfitter program
(16).
Bioassays of
-lactamase activity.
Cultures of the
isolates and transconjugants were grown overnight as lawns on nutrient
agar plates and then resuspended in 2 ml of sterile 10 mM phosphate
buffer, pH 7.0, chilled on ice, and sonicated for two or three 10-s
bursts at an amplitude of 15 µm. Debris was removed by centrifugation
at 16,000 × g for 15 min, and 200 µl of the
supernatants was mixed with 200 µl of a 40-µg/ml solution of
ceftazidime in 10 mM phosphate buffer, pH 7.0. As a control,
ceftazidime solutions (40 µg/ml) were incubated with similar extracts
of P. aeruginosa PU21 containing or not containing plasmid
pMLH51, pMLH52, or pMLH53. After incubation for 1 h at 37°C,
samples of the mixtures were transferred to wells (0.7-cm diameter) in
a 23- by 23-cm bioassay plate containing 120 ml of Mueller-Hinton agar
seeded with 0.6 ml of a 500-fold dilution of an overnight culture of
E. coli NCTC 10418. The plate was incubated for 18 h at
37°C, and inhibition zones were compared to those for the untreated drug.
Nucleotide sequence accession number. The GenBank database accession number for the sequence shown in Fig. 1 is AF043100.
| |
RESULTS |
|---|
|
|
|---|
Susceptibilities,
-lactamases, and plasmids of isolates 906 and
961.
Isolates 906 and 961 exhibited similar antibiograms. Both
were highly resistant to ceftazidime (MICs, 128 to 256 µg/ml) and were 4- to 16-fold less susceptible than is typical for the species (3) to cefoperazone, ceftriaxone, cefepime, cefpirome, and cefsulodin (Table 1). On the other hand,
the MICs recorded for aztreonam (2 to 4 µg/ml), carbapenems (1 to 4 µg/ml), piperacillin (8 µg/ml), and carbenicillin (64 µg/ml) were
no higher than is typical for P. aeruginosa. Ceftazidime
resistance was only reduced twofold by clavulanate and was not affected
by tazobactam.
|
-lactamase in both isolates, and electrophoresis revealed that each
isolate carried a 325-kb plasmid.
Transfer of ceftazidime resistance to P. aeruginosa
PU21.
Attempts to transfer ceftazidime resistance conjugatively
from isolates 906 and 961 to P. aeruginosa PU21 were
unsuccessful, but transfer was achieved after plasmid pUZ8 was inserted
into the isolates. The transconjugant of strain 906 acquired a 90-kb plasmid, and that of 961 acquired a 60-kb plasmid, compared to 40 kb
for native pUZ8. Both transconjugants expressed the pI-6.2
-lactamase. Both also showed similar resistance profiles and were
particularly resistant to ceftazidime (MIC, > 256 µg/ml, compared
with 4 µg/ml for P. aeruginosa PU21). The MICs of other cephalosporins and piperacillin were raised 4- to 16-fold by
acquisition of the plasmids. The transconjugants remained as
susceptible as strain PU21 to imipenem and meropenem and were not
significantly (i.e., more than twofold) more resistant to
carbenicillin. MICs of piperacillin, carbenicillin, and ceftazidime
were not reduced by more than twofold by clavulanate or tazobactam at 4 µg/ml. Similar resistance patterns
though with carbenicillin
resistance
were seen for P. aeruginosa PU21(pMLH52) and
PU21(pMLH53) with OXA-11 and -14 enzymes, respectively, whereas
P. aeruginosa PU21(pMLH51), with classical OXA-10 enzyme,
was resistant only to piperacillin, carbenicillin, and cefoperazone.
Restriction patterns of DNA digests and hybridization with gene probe. Total DNA was extracted from isolates 906, 961, ABD, 455 and, as a negative control, P. aeruginosa PU21. After digestion with BamHI, the fragments were separated by agarose gel electrophoresis. Isolates 906 and 961 gave identical restriction patterns, suggesting that they represented a single strain, whereas a different pattern was seen for isolates 455 and ABD. Following blotting to nylon membranes, DNA from isolates 906, 961, ABD, and 455 hybridized with a blaOXA-10 probe whereas DNA from PU21 did not do so. Isolates 906 and 961 carried the gene corresponding to blaOXA-10 on a 3.5-kb BamHI fragment indistinguishable from that yielded by isolates ABD and 455. Additionally, it was found that the 325-kb plasmid from isolates 906 and 961 and the recombinant plasmids from their PU21 transconjugants hybridized with the blaOXA-10 probe.
Gene sequencing.
Sequence analysis was performed on the genes
encoding the OXA-10-related
-lactamases in isolates 906 and 961. The
section sequenced corresponded to nucleotide positions 156 to 931 of
blaOXA-10 (13) and excluded only the
regions coding for the first 16 amino acids (which are part of the
signal peptide) and the last 5 residues (Fig. 1). Both isolates had the
same new OXA-10-derived
-lactamase, with glycine replaced by
asparagine at position 157 and alanine changed to threonine at position
124. This enzyme was named OXA-16, and its 325-kb encoding plasmid was
called pMLH57.
Purification of OXA-10 and -16
-lactamases.
Identical
methods were used to purify OXA-10 and -16
-lactamases, except that
the pH for the cation exchange was increased from 4.9 to 5.0 for
OXA-16. Concentrations of salt needed to elute OXA-16 and OXA-10
enzymes were 91 and 81 mM, respectively, in the anion exchange and 160 and 200 mM, respectively, in the cation exchange. Both
-lactamases
eluted from the cation exchanger after all the contaminant proteins,
and the purity of each exceeded 95%, as judged by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Twelve liters of culture of
isolate 906 yielded 0.4 mg of OXA-16
-lactamase, and 12 liters of
P. aeruginosa PU21(pMLH51) culture yielded 3.75 mg of OXA-10
-lactamase.
Hydrolysis of
-lactams by OXA-10 and -16
-lactamases.
For many substrates, the time course for hydrolysis showed biphasic
behavior, complicating analysis. Hydrolysis curves were characterized
as biphasic if the rate within the first minute was at least 20%
higher than the steady-state rate immediately afterward. Smaller
differences were not analyzed, since they could not be accurately
measured during the short period while the rate was changing, but they
were observed frequently.
-lactamase, the hydrolysis curves of
penicillin G and ceftriaxone were linear, whereas biphasic kinetics were seen for ampicillin, carbenicillin, oxacillin, cloxacillin, and
cephaloridine. The initial rate/steady-state rate ratios varied with
the substrate concentration, but for ampicillin they were between 1.2 and 1.7 and for carbenicillin they ranged from 3.4 to 3.0, while the
highest ratio was 16, for cloxacillin.
In the case of OXA-16
-lactamase, the hydrolysis curves were linear
for cephalothin and ceftriaxone and biphasic for penicillin G,
ampicillin, carbenicillin, oxacillin, cloxacillin, cephaloridine, and
cefotaxime. The initial rate/steady-state rate ratios were similar to
those for OXA-10 enzyme.
OXA-10 enzyme showed its lowest steady-state Km
values (40 to 60 µM) for penicillin G, cephalothin, and ceftriaxone,
whereas the highest values (>2,000 µM) were for cloxacillin and
cephaloridine (Table 2).
Between these extremes were ampicillin, carbenicillin, and oxacillin,
with Km values around 200 µM. The turnover
number (kcat) was less than 10 s
1
for cephalothin, cefotaxime, and ceftriaxone and between 30 and 90 s
1 for carbenicillin, penicillin G, and cephaloridine but
exceeded 500 s
1 for ampicillin, oxacillin, and
cloxacillin. The best substrates in terms of linear or steady-state
efficiency (kcat/Km) were
oxacillin and ampicillin, followed by penicillin G, whereas
kcat/Km values were at
least 10-fold lower for the other substrates. For substrates showing
biphasic kinetics, higher affinity was seen in the initial phase,
except with carbenicillin; thus, the ratios of
Km values in the steady-state and initial phases
(KmSS/Kmo)
were 2.3 and 2.4 for oxacillin and cloxacillin, respectively, 5.9 for
cephaloridine, and 0.53 for carbenicillin. The ratios of initial and
steady-state kcat values
(kcato/kcatSS)
were 2 for cephaloridine, 4 to 5 for carbenicillin and cloxacillin, and
10 for ampicillin and oxacillin, but the two parameters were similar
for oxacillin. The efficiency
(kcat/Km) in the initial phase was two- to threefold greater than in the steady-state phase except for cloxacillin, where a 12-fold differential was observed.
|
1 for cephalothin, cefotaxime, and ceftriaxone; between
20 and 100 s
1 for carbenicillin, ampicillin, and
penicillin G; and exceeded 200 s
1 for oxacillin and
cloxacillin. The best substrate in terms of kcatSS/KmSS
values was penicillin G, followed by ampicillin and oxacillin. Km values for nonlinear substrates were 1.4- to
2.2-fold lower in the initial phase than at steady state, except with
carbenicillin and cephaloridine, where the two parameters were similar.
kcato was 1.5- to 4.5-fold higher
than kcatSS for ampicillin,
carbenicillin, cloxacillin, cephaloridine, and cefotaxime, but the two
parameters were little different for oxacillin. Hydrolysis was
eightfold more efficient in terms of
kcat/Km values in the
initial phase than at steady state for cloxacillin and 1.6- to 3.8-fold
more efficient for carbenicillin, ampicillin, oxacillin, cephaloridine,
and cefotaxime.
No hydrolysis of ceftazidime by OXA-16 enzyme was detected by
spectrophotometry (Table 2); nevertheless, the enzyme gave considerable
ceftazidime resistance (Table 1). Therefore, bioassay with crude
extracts was performed and likewise failed to detect inactivation of
ceftazidime by either OXA-10 or -16 enzyme, whereas this assay
confirmed inactivation hydrolysis of ceftazidime by OXA-11 and -14
-lactamases, as had been detected previously by spectrophotometry
(5, 11).
| |
DISCUSSION |
|---|
|
|
|---|
OXA-16 is the third extended-spectrum mutant of OXA-10 (PSE-2)
-lactamase to be described, following OXA-11 (11) and
OXA-14 (5). All these mutants have asparagine replacing
glycine at position 157; in addition OXA-16 had threonine replacing
alanine at position 124 and OXA-11 has serine replacing asparagine at residue 143. Mutation at position 157 thus seems critical to
ceftazidime resistance, and it was also noted in a ceftazidime-selected
laboratory mutant of OXA-13
-lactamase, which is a more distant
relative of OXA-10 (23). A further ESBL mutant of OXA-10,
OXA-17, lacks the substitution at position 157 and does not confer
significant ceftazidime resistance, although it does compromise other
oxyimino aminothiazolyl cephalosporins (8).
Acquisition of OXA-16 enzyme by P. aeruginosa PU21 conferred
resistance to ceftazidime (especially), ceftriaxone, cefepime, cefpirome, cefoperazone, latamoxef, and piperacillin, as did
acquisition of OXA-11 or -14 enzymes (Table 1) (5, 11).
However, production of OXA-16 enzyme caused only a twofold rise in the
MIC of carbenicillin for strain PU21, whereas OXA-11 and -14 enzymes
gave greater protection, as does classical OXA-10 enzyme. Neither
OXA-16
-lactamase nor any other OXA-10 mutant conferred resistance
to carbapenems. A final general feature was that the resistance
caused by OXA-10-related enzymes, including OXA-16, was reduced only
two- to fourfold by clavulanate at 4 µg/ml and not at all by
tazobactam at 4 µg/ml (Table 2).
The original OXA-16 producers
P. aeruginosa 906 and 961
were less resistant than their PU21 transconjugants to penicillins and cephalosporins and retained susceptibility to carbenicillin, piperacillin, and aztreonam, both relative to National Committee for
Clinical Laboratory Standards breakpoints (25) and with regard to typical MICs for P. aeruginosa isolates without
acquired resistance (3). This apparent susceptibility may
have reflected lower
-lactamase production in the clinical isolates
than in the transconjugants, due to a difference in the plasmid copy
number, or a combination of greater permeability and weaker efflux
function in the isolates. These aspects were not investigated.
Both OXA-16 producers were isolated from burn patients at Hacettepe
University Hospital in Ankara, Turkey, which is the same establishment
where the first producers of OXA-11 and -14 enzymes
P. aeruginosa ABD and 455, respectively
were found. Isolates 906 and
961 appeared to be replicates, based on the similarity of the
BamHI restriction profiles of their DNAs and on the fact
that each carried the OXA-16 gene on a nonconjugative 325-kb plasmid. They were less closely related to isolates ABD and 455, which themselves appear to be replicates, apart from the point mutation that
distinguishes their
-lactamases (5, 11). These latter organisms yielded a BamHI restriction profile different from
that of isolates 906 and 961 and carried their
blaOXA genes on 475-kb plasmids, which were
conjugatively self-transmissible to P. aeruginosa PU21.
However, a common ancestor is suggested by the fact the OXA-10-related
genes were carried by 3.5-kb BamHI fragments in all these
OXA-11, -14, and -16 producers.
The OXA-16-encoding gene of the present isolates appeared to be located
within a transposon, as judged by its ability to transfer to plasmid
pUZ8. The gene encoding classical OXA-10
-lactamase was previously
shown to be transposon associated (1), whereas attempts to
achieve transposition of blaOXA-11 and
blaOXA-14 were consistently unsuccessful
(5, 11). Curiously, the OXA-16-encoding pUZ8 recombinant
plasmid obtained from isolate 961 was smaller than that from isolate
906 (60 kb compared with 90 kb). It is possible that another transposon
besides that carrying blaOXA-16 had inserted
into pUZ8-906, whereas only the OXA-16 transposon had inserted into
pUZ8-961; alternatively, the pUZ8 plasmid may have acquired two copies
of the OXA-16 transposon, since the size of its insert was within
experimental error of twice the size of the insert in pUZ8-961. Yet
another possibility is that the two isolates had different
blaOXA-16-coding transposons, but this seems
unlikely, both because of the general similarity of the organisms and
because it would imply an exceptionally large size (50 kb) for the
transposon from isolate 906.
Kinetic studies were undertaken on purified OXA-16 enzyme, with OXA-10
as a comparator. The ability of OXA-16 to give increased cephalosporin
resistance could not be correlated with increased hydrolytic activity
in vitro, regardless of whether kcat or
kcat/Km was taken as a
measure of activity. This contrasts with ESBL mutants of TEM and SHV
-lactamases, which consistently exhibit greatly increased in vitro
activity against the cephalosporins to which they confer resistance
(2). Most strikingly, attempts to explain the ability of
OXA-16 enzyme to confer ceftazidime resistance were unsuccessful. In
the case of OXA-11 enzyme, ceftazidime resistance was associated with
an increased kcat/Km
ratio, owing to a reduced km compared to that of
OXA-10 enzyme (11), but no such association was found for
OXA-16; indeed, it proved impossible to detect ceftazidime hydrolysis
by OXA-16, even by a very sensitive bioassay. A possible explanation
for these anomalies may lie in the biphasic kinetics often seen for
OXA-10-related
-lactamases. Such kinetics were reported for several
substrates with OXA-10 itself (17) and with OXA-16 (this
study) (Table 2) and for all substrates with OXA-14 (5, 9).
The general pattern is for the enzyme to swiftly convert from a more
active to a less active form, and data for OXA-14 suggests that this
may reflect a dilution-dependent monomer-dimer interconversion
(9). Given that the
-lactamase in the cell periplasm is
more concentrated than in any practicable assay (18), it may
be that OXA-10 family enzymes are in a more active form in the cell
than in the assay.
In summary, this paper has described OXA-16, the third ESBL mutant of
OXA-10 enzyme. Like the previously described OXA-11 and -14 mutants,
OXA-16 had glycine replaced by aspartate at position 157 and had an
increased ability to confer resistance to ceftazidime and, to a lesser
extent, to other oxyimino aminothiazolyl cephalosporins. All three
mutants have been recorded from P. aeruginosa isolates collected at a single Turkish hospital, though we are now also aware of
such mutants at a second hospital in the same city (28). Their evolution parallels that of the TEM and SHV ESBL mutants, though
the relationships between resistance and hydrolytic activity are much
less clear. The emergence of OXA ESBLs in P. aeruginosa is
disturbing, since it narrows the range of therapeutic options. A
particular concern is that, unlike with TEM, SHV, and PER ESBLs, resistance could not be overcome with clavulanic acid or with penicillanic acid sulfone
-lactamase inhibitors.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Pharma Research Preclinical Infectious Disease, CH-4070 Basel, Switzerland. Phone: 41-61-6880537. Fax: 41-61-6882729. E-mail franck.danel{at}roche.com.
Present address: Antibiotic Reference Unit, Laboratory of Hospital
Infection, Central Public Health Laboratory, London NW9 5HT, United Kingdom.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bissonnette, L., and P. H. Roy.
1992.
Characterization of In0 of Pseudomonas aeruginosa plasmid pVS1, an ancestor of integrons of multiresistance plasmids and transposons of gram-negative bacteria.
J. Bacteriol.
174:1248-1257 |
| 2. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 3. |
Chen, H. Y.,
M. Yuan,
I. B. Ibrahim-Elmagboul, and D. M. Livermore.
1995.
National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.
J. Antimicrob. Chemother.
35:521-534 |
| 4. |
Chen, H. Y.,
M. Yuan, and D. M. Livermore.
1995.
Mechanisms of resistance to -lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.
J. Med. Microbiol.
43:300-309 |
| 5. |
Danel, F.,
L. M. C. Hall,
D. Gur, and D. M. Livermore.
1995.
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
39:1881-1884[Abstract].
|
| 6. |
Danel, F.,
L. M. C. Hall,
D. Gur,
H. E. Akalin, and D. M. Livermore.
1995.
Transferable production of PER-1 -lactamase in Pseudomonas aeruginosa.
J. Antimicrob. Chemother.
35:281-294 |
| 7. |
Danel, F.,
L. M. C. Hall,
D. Gur, and D. M. Livermore.
1997.
OXA-15, an extended-spectrum variant of OXA-2 -lactamase, isolated from a Pseudomonas aeruginosa strain.
Antimicrob. Agents Chemother.
41:785-790[Abstract].
|
| 8. |
Danel, F.,
L. M. C. Hall,
D. Gur, and D. M. Livermore.
1996.
Multiple secondary -lactamase, including a new OXA-10 mutant, in two Turkish P. aeruginosa isolates, abstr. T119.
In
Abstracts of the European Congress of Chemotherapy.
|
| 9. |
Danel, F.
1997.
Extended-spectrum -lactamases from Pseudomonas aeruginosa isolates collected in Turkey. Ph.D. thesis.
University of London, London, United Kingdom.
|
| 10. |
De Meester, F.,
B. Joris,
G. Reckinger,
C. Bellefroid-Bourguignon,
J. M. Frère, and S. G. Waley.
1987.
Automated analysis of enzyme inactivation phenomena. Application to -lactamases and DD-peptidases.
Biochem. Pharmacol.
36:2393-2403[Medline].
|
| 11. |
Hall, L. M. C.,
D. M. Livermore,
D. Gur,
M. Akova, and H. E. Akalin.
1993.
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
37:1637-1644 |
| 12. |
Hedges, R. W., and M. Matthew.
1979.
Acquisition by Escherichia coli of plasmid-borne -lactamases normally confined to Pseudomonas spp.
Plasmid
2:269-278[Medline].
|
| 13. |
Huovinen, P.,
S. Huovinen, and G. A. Jacoby.
1988.
Sequence of PSE-2 -lactamase.
Antimicrob. Agents Chemother.
32:134-136 |
| 14. |
Jacoby, G. A.
1974.
Properties of R-plasmids determining gentamicin-resistance by acetylation in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
6:239-252 |
| 15. |
Kado, C. I., and S. T. Liu.
1981.
Rapid procedure for detection and isolation of large and small plasmids.
J. Bacteriol.
145:1365-1373 |
| 16. | Leatherbarrow, R. J. 1987. Enzfitter: a non-linear regression data analysis program for the IBM PC/P52. Elsevier Biosoft, Cambridge, United Kingdom. |
| 17. |
Ledent, P.,
X. Raquet,
B. Joris,
J. Van-Beemen, and J. M. Frère.
1993.
A comparative study of Class D -lactamases.
Biochem. J.
292:555-562.
|
| 18. | Livermore, D. M., K. W. Davy, and J. D. Williams. 1985. Cephalosporin resistance in Pseudomonas aeruginosa, with special reference to the proposed trapping of antibiotics by beta-lactamase. Chemioterapia 4:28-35[Medline]. |
| 19. |
Livermore, D. M.
1995.
-Lactamases in laboratory and clinical resistance.
Clin. Microbiol. Rev.
8:557-584[Abstract].
|
| 20. |
Livermore, D. M.,
J. P. Maskell, and J. D. Williams.
1984.
Detection of PSE-2 -lactamase in enterobacteria.
Antimicrob. Agents Chemother.
25:268-272 |
| 21. | Lugtenberg, B., J. Meijers, R. Peters, P. Van der Hoek, and L. Van Alphen. 1975. Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett. 58:254-258[Medline]. |
| 22. |
Matthew, M.,
A. M. Harris,
M. J. Marshall, and G. W. Ross.
1975.
The use of analytical isoelectric focusing for detection and identification of -lactamases.
J. Gen. Microbiol.
88:169-175[Medline].
|
| 23. |
Mugnier, P.,
I. Podglajen,
L. Gutmann, and E. Collatz.
1994.
Cloning and nucleotide sequence analysis of two Pseudomonas aeruginosa genes encoding the novel OXA-type -lactamase variants OXA-12 and OXA-13, susceptible to inhibition by imipenem, abstr. C98, p. 139.
In
Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 24. |
Mugnier, P.,
P. Dubroust,
I. Casin,
G. Arlet, and E. Collatz.
1996.
A TEM-derived extended-spectrum -lactamase in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
40:2488-2493[Abstract].
|
| 25. | National Committee for Clinical Laboratory Standards. 1987. Methods for determining bactericidal activity of antimicrobial agents. M36-P, vol. 7, no. 2. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 26. |
Nordmann, P., and T. Naas.
1994.
Sequence analysis of PER-1 extended-spectrum -lactamase from Pseudomonas aeruginosa and comparison with class A -lactamases.
Antimicrob. Agents Chemother.
38:104-114 |
| 27. |
Nordmann, P.,
E. Ronco,
T. Naas,
C. Duport,
Y. Michel-Briand, and R. Labia.
1993.
Characterization of a novel extended-spectrum -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
37:962-969 |
| 28. |
Ozen, Y.,
D. Arman, and D. M. Livermore.
1996.
Extended-spectrum -lactamases in P. aeruginosa isolates from Ankara University Hospital, abstr. 403, p. 188.
In
Abstracts of the X Mediterranean Congress on Chemotherapy.
|
| 29. |
Summers, A. O., and G. A. Jacoby.
1977.
Plasmid-determined resistance to tellurium compounds.
J. Bacteriol.
129:276-281 |
| 30. |
Vahaboglu, H.,
R. Öztürk,
G. Aygün,
F. Co kunkan,
A. Yaman,
A. Kaygusuz,
H. Leblebicioglu,
I. Balik,
K. Aydin, and M. Otkun.
1997.
Widespread detection of PER-1-type extended-spectrum -lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study.
Antimicrob. Agents Chemother.
41:2265-2269[Abstract].
|
| 31. |
Vivian, A.
1994.
Plasmid expansion?
Microbiology
140:213-214 |
| 32. |
Watanabe, M.,
S. Iyobe,
M. Inoue, and S. Mitsuhashi.
1991.
Transferable imipenem resistance in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
35:147-151 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»